RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1743125
A Rare Case of Life-Threatening Extensive Mucocutaneous Adverse Reaction Induced by Docetaxel in a Breast Cancer Patient: Toxic Epidermal Necrolysis, a Case Report with Review of Literature
Funding None.
Abstract
Fever and extensive necrosis with 30% or more epidermal involvement along with mucous membrane is known as toxic epidermal necrolysis (TEN). It is a life-threatening mucocutaneous disease and is usually drug induced. We report a rare case of docetaxel-induced TEN. A patient with metastatic breast carcinoma received single agent docetaxel and developed severe skin and mucous membrane reaction involving more than 30% of the skin, and managed conservatively in intensive care unit but she succumbed to her illness. Although common toxicities reported with docetaxel include alopecia, nail damage, myelosuppression, and erythema multiforme major, TEN after docetaxel is very rare and can be a life-threatening complication as in our case.
Ethics
The authors certify that they have obtained an Ethics committee approval for publication (ECR/748/Inst/MP2015-EE/18, dated: 22 October 2021) from the institutional ethics committee of Sri Aurobindo Institute of Medical Sciences.
Publikationsverlauf
Artikel online veröffentlicht:
28. Juni 2022
© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000; 1 (01) 32-40 , discussion 41–42
- 2 Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36 (02) 99-114
- 3 Chen M, Crowson AN, Woofter M, Luca MB, Magro CM. Docetaxel (Taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31 (04) 818-820
- 4 Vasudevan B, Sawhney MP, Sharma N. Docetaxel-induced photolichenoid eruption. Indian J Pharmacol 2009; 41 (04) 203-204
- 5 Moisidis C, Möbus V. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 2005; 271 (03) 267-269
- 6 Aydogan I, Kavak A, Parlak AH, Alper M, Annakkaya AN, Erbas M. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 2005; 19 (03) 345-347
- 7 Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139 (08) 683-693
- 8 Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129 (04) 466-468
- 9 Nassif A, Bensussan A, Boumsell L. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114 (05) 1209-1215
- 10 Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129 (06) 1562-9.e5
- 11 Roujeau JC, Bricard G, Nicolas JF. Drug-induced epidermal necrolysis: important new piece to end the puzzle. J Allergy Clin Immunol 2011; 128 (06) 1277-1278
- 12 Ko TM, Chung WH, Wei CY. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128 (06) 1266-1276.e11
- 13 Adam J, Wuillemin N, Watkins S. et al. Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. PLoS One 2014; 9 (04) e95339
- 14 Ostrov DA, Grant BJ, Pompeu YA. et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109 (25) 9959-9964
- 15 Rasmussen JE. Toxic epidermal necrolysis. A review of 75 cases in children. Arch Dermatol 1975; 111 (09) 1135-1139
- 16 Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58 (01) 33-40
- 17 Bastuji Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for TEN. J Invest Dermatol 2000; 115: 149-153